Journal of Oral and Maxillofacial Surgery
Volume 64, Issue 6 , Pages 917-923 , June 2006

Bisphosphonates Are Associated With Increased Risk for Jaw Surgery in Medical Claims Data: Is it Osteonecrosis?

  • Athanasios I. Zavras, DMD, MS, DrMS

      Affiliations

    • Assistant Professor, Department of Oral Health Policy & Epidemiology, Harvard School of Dental Medicine, Boston, MA; Sceintific Affairs Consultant, Ingenix, Eden Prairie, MN
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Zavras: Department of Health Policy & Epidemiology, Harvard School of Dental Medicine, 188 Longwood Ave, Boston, MA 02115
    • ,
  • Shao Zhu, MD

      Affiliations

    • Medical Statistician, i3 Epidemiology, Ingenix, Eden Prairie, MN

References 

  1. Fleisch H , Rusell RG , Bisaz S , et al.   The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution . Calcif Tissue Res . 1968;10(supp1):10a
  2. Little DG , Peat RA , McEvoy A , et al.   Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young wistar rats . J Bone Miner Res . 2003;18:2016
  3. Hughes DE , MacDonald BR , Rusell RG , et al.   Inhibition of osteoclast-like cell formation by bisphosphonates in long term cultures of human bone marrow . J Clin Invest . 1989;83:1930
  4. Sahni M , Guenther H , Fleisch H , et al.   Bisphosphonates act on rat bone resorption through the mediation of osteoblasts . J Clin Invest . 1993;91:2004
  5. Brixen K: Bisphosphonates as a potential treatment for osteogenesis imperfecta. Proceedings of the OIFE meeting, September 25-26, 1998. Vingsted, Denmark. Available at: www.brandx.net/markgash/bispho.html. Accessed February 24, 2006
  6. Astrand J , Aspenberg P . Systemic alendronate prevents resorption of necrotic bone revascularization. A bone chamber study in rats . BMC Musculoskelet Disord . 2002;3:19
  7. Gralow J . Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer . Clin Breast Cancer . 2005;5(suppl 2):S54
  8. Bone HG , Hosking D, Devogelaer JP , et al.  Alendronate Phase III Osteoporosis Treatment Study Group   Ten years’ experience with alendronate for osteoporosis in postmenopausal women . N Engl J Med . 2004;350:1189
  9. Marx RE . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws (A growing epidemic) . J Oral Maxillofac Surg . 2003;61:1115
  10. Ruggiero SL , Mehrotra B , Rosenberg TJ , et al.   Osteonecrosis of the jaws associated with the use of bisphosphonates (A review of 63 cases) . J Oral Maxillofac Surg . 2004;62:527
  11. Lugassy G , Shaham R , Nemets A , et al.   Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma (A new clinical entity) . Am J Med . 2004;117:440
  12. Bagan JV , Murillo J , Jimenez Y , et al.   Avascular jaw osteonecrosis in association with cancer chemotherapy (Series of 10 cases) . J Oral Pathol Med . 2005;34:120
  13. Migliorati CA , Schubert MM , Peterson DE , et al.   Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone . Cancer . 2005;104:83
  14. Schirmer I , Peters H , Reichart PA , et al.   Bisphosphonates and osteonecrosis of the jaw . Mund Kiefer Gesichtschir . 2005;9:239
  15. Durie BGM , Katz M , Crowley J . Osteonecrosis of the jaw and bisphosphonates . N Engl J Med . 2005;353:99
  16. Schwartz HC . Osteonecrosis and bisphosphonates (Correlation versus causation) . J Oral Maxillofac Surg . 2004;62:763
  17. Hellstein JW , Marek CL . Bisphosphonate osteochemonecrosis (bis-phossy jaw) (Is this phossy jaw of the 21st century?) . J Oral Maxillofac Surg . 2005;63:682
  18. Woo SB , Hande K , Richardson PG . Osteonecrosis of the jaw and bisphosphonates . N Engl J Med . 2005;353:100
  19. Maerevoet M , Martin C , Duck L . Osteonecrosis of the jaw and bisphosphonates . N Engl J Med . 2005;353:100
  20. Melo MD , Obeid G . Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy . J Can Dent Assoc . 2005;71:111
  21. Pamer C, McCloskey C: Postmarketing safety assessment of osteonecrosis of the jaw. Pamidronate and zoledronic acid. Available at: www.fda.gov/ohrms/dockets/ac/05/slides/2005-4095S2_03_02-FDA-Pamer.ppt. Accessed April 7, 2005
  22. Summary of ONJ cases from retrospective chart review at MD Anderson Cancer Center. Novartis Pharmaceutical Corporation. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_02_07-Novartis-Zometa-App6.pdf±onj&restrict=&site=FDA&output=xml_no_dtd&client=FDA&access=p&lr=&proxystylesheet=FDA&oe=. Accessed April 7, 2005
  23. Drug linked to death of jawbone. USA Today. March 13, 2005. Available at: http://www.usatoday.com/news/health/2005-03-13-jawbone-deaths_x.htm#. Accessed April 6, 2005
  24. Fournier P , Boissier S , Filleur S , et al.   Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats . Cancer Res . 2002;62:6538
  25. Whyte MP , Wenkert D , Clements KL , et al.   Bisphosphonate-induced osteopetrosis . N Engl J Med . 2003;349:457

PII: S0278-2391(06)00231-X

doi: 10.1016/j.joms.2006.02.011

Journal of Oral and Maxillofacial Surgery
Volume 64, Issue 6 , Pages 917-923 , June 2006

Article Tools